Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimeras [0.03%]
利用CD137适配体-shRNA嵌合分子靶向肿瘤内调节性T细胞
Kang Yi Lee,Yu Mei,Haiyan Liu et al.
Kang Yi Lee et al.
Introduction: The cytokine CD137 (TNFRSF9, 4-1BB) is best known as a T cell costimulatory molecule. However, CD137 is also part of a negative feedback mechanism that limits T cell activation, and that is employed by regul...
Sarah Danson,Robert P Jones,Kristina Duggleby et al.
Sarah Danson et al.
Cancer vaccines offer transformative potential in oncology, especially with advances in mRNA technologies. To accelerate advances in cancer vaccine research and capitalize on its COVID-19 vaccine leadership, the UK Government has launched t...
Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors [0.03%]
抗实体瘤MAGE-A4特异性TCR-NK细胞的临床前评估
Margherita Boieri,Justyna Kmiecik,Maja Sandve et al.
Margherita Boieri et al.
T cell (Tc) receptor (TCR)-based cell therapies have shown clinical efficacy across many cancer types and represent an attractive strategy for targeting solid tumors. However, the immunosuppressive tumor microenvironment, downregulation of ...
Targeted 19F MRI for molecular imaging of the immune response and its theranostics [0.03%]
用于免疫反应及其诊疗的19F磁共振成像分子影像学研究
Pascal Bouvain,Sebastian Temme,Ulrich Flögel
Pascal Bouvain
The in vivo visualization of inflammatory processes offers not only the possibility of localizing disease but also of monitoring its progression over time. Among available imaging modalities, combined 1H/19F MRI has emerged as a powerful te...
[89Zr]Zr-DFO-avelumab accumulation in resectable non-small cell lung carcinoma indicates a suppressive tumor microenvironment amendable to neoadjuvant avelumab treatment [0.03%]
89Zr标记的DFO-avelumab在可切除非小细胞肺癌中的聚集表明了一个有利于新辅助avelumab治疗的免疫抑制性肿瘤微环境
Sarah R Verhoeff,Evelien A J van Genugten,Iris A E van der Hoorn et al.
Sarah R Verhoeff et al.
Background: Immune checkpoint inhibitor treatment in non-small cell lung cancer (NSCLC) expands to early stages of disease. The neoadjuvant setting allows to investigate the mechanism-of-action of immune therapy using mol...
A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritis [0.03%]
抗CD3单克隆抗体治疗类风湿性关节炎的I期试验性药物研究
Catherine A Lawson,Rachel Harry,Bridget Griffiths et al.
Catherine A Lawson et al.
Introduction: An Fc-mutated chimeric aglycosyl anti-CD3 monoclonal antibody (mAb), otelixizumab, has been used successfully to treat renal transplant rejection and type 1 diabetes, with reduced toxicity compared with trad...
Callum Blee,Munitta Muthana,Greg Wells et al.
Callum Blee et al.
Cancer vaccines and oncolytic viruses (OVs) represent promising immunotherapeutic strategies, harnessing adaptive and innate immune responses for targeted tumour eradication. Cancer vaccines aim to induce tumour-specific cytotoxic T lymphoc...
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis [0.03%]
CD40L和IL-4通过HLA-E:NKG2A轴抑制抗体依赖的自然杀伤细胞毒性作用
Lara V Graham,Ludmila Horehajova,Marco V Haselager et al.
Lara V Graham et al.
Background: Anti-CD20 antibodies are first-line treatments for B cell malignancies. Natural killer (NK) cells are important mediators of anti-CD20 antibody efficacy in humans through antibody-dependent cellular cytotoxici...
Correction to: Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients [0.03%]
Correction to：应用人群机理模型寻找一个月内淋巴瘤患者嵌合抗原受体T细胞动力学的决定因素
[This corrects the article DOI: 10.1093/immadv/ltaf001.]. © The Author(s) 2025. Published by Oxford University Press on behalf of the British Society fo...
Published Erratum
Immunotherapy advances. 2025 Sep 10;5(1):ltaf028. DOI:10.1093/immadv/ltaf028 2025
Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients [0.03%]
应用人群机制模型寻找月内淋巴瘤患者嵌合抗原受体T细胞动力学的决定因素
Liam V Brown,Mark McConnell,Robert Rosler et al.
Liam V Brown et al.
Background: Chimeric antigen receptor (CAR) T-cells have been utilized for the treatment of several malignancies, including Non-Hodgkin lymphomas. A myriad of product- and patient-specific factors determines the extent of...